AUPH News and Press, Aurinia Pharmaceuticals Inc

— Multitarget Approach Has Potential to Further Improve Outcomes in This Disease Characterized by Continued Unmet Need — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of ...

2026-06-07 08:17:26 ET Kevin Tang, Chief Executive Officer of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) , reported the purchase of 814,606 common shares across multiple transactions between May 29, 2026, and June 2, 2026, according to a SEC Form 4 filing . Transaction val...

2026-06-04 08:33:06 ET Thesis Read the full article on Seeking Alpha For further details see: Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow

— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS ® in the treatment of lupus nephritis is being presented at ...

2026-06-03 13:22:02 ET Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call June 3, 2026 12:00 PM EDT... Read the full article on Seeking Alpha For further details see: Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript

2026-06-03 03:54:24 ET More on Aurinia Pharma Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade) Aurinia Pharma GAAP EPS of $0.25 beats by $0.05, revenue of $77.7M beats by $0.7...

TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC. Canada NewsWire SAN DIEGO , June 3, 2026 /CNW/ - Tang Capital Management, LLC announces that on June 2, 2026, it acquired 206,005 common shares (the " Common Shares ") of Aurinia Pharm...

Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer for Kezar Life Sciences. The offer resulted in 5,927,580 shares being tendered, representing 80.24%...

2026-05-11 09:57:46 ET Investment Overview - FDA Commissioner Marty Makary On The Brink A couple of weeks ago, I covered the news that Replimmune ( REPL ), a Massachusetts-based biotech, had had its Biologics License Application ("BLA") requesting approval for its lead drug ...

2026-05-07 08:05:54 ET More on Aurinia Pharma Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade) Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript Aur...